Volume : 12, Issue : 10, October – 2025
Title:
EVALUATION OF HEPATOPROTECTIVE ACTIVITY OF ETHANOLIC EXTRACT OF WITHANIA SOMNIFERA IN INDUCED LIVER INJURY IN RATS
Authors :
Bollu Satya Sudha*, Mrs. Geetha Vani, Dr. D. Venkata Ramana
Abstract :
In this study we investigated the in vivo Hepatoprotective activity of ethanolic extract of Withania somnifera in induced hepatotoxicity using wistar rats of either sex as model. Hepatotoxicity was induced by the administration of 3% CMC per 100g body weight). Withania somnifera extract at different dose levels (200 and 400mg/kg, p.o.) showed the dose dependant hepatoprotective effect and was compared with well known standard hepatoprotective Silymarain (100mg/kg).
The rats were divided into five groups with three rats in each for three models. Group I (Control) served as normal and received the vehicle alone (Sterile distilled water, 10 ml/kg, p.o.) for 21 days. Group II (control and 40% ethanol) animals on the 21 day. Group III Received 40% ethanol v/v (2.0ml/l00g body wt, p.o.) for 21 days and standard drug silymarin (25 mg/kg. p.o.) for 21 days once daily and IV were treated with 40% ethanol and Ethanolic extract Withania somnifera (400 mg/kg) 21 days once daily. Group V was treated with Received 40% ethanol and Ethanolic extract of Withania somnifera (200 mg/kg) 21 days once daily the animals were sacrificed 48 h after the last injection of hepatotoxic drugs under mild ether anesthesia. The blood was collected and allowed to stand for 30 min at 37°C and then centrifuged to separate the serum to estimate various biochemical parameters.
In hepatoprotective studies, the toxicity elevated levels of serum marker enzymes Total Bilirubin ALT, AST, ALP, SGOP and SGPT levels. Ethanol induced hepatotoxicity was significantly prevented by pretreatment ethanolic extract of leaves. Decrease in wet liver weight, reduction in elevated biochemical parameter levels like serum SGPT, SGOT, and total bilirubin, after treatment with Ethanolic extract of Withania somnifera confirmed the hepatoprotective effect of extract under study. In liver injury models in rats restoration of hepatic cells with minor fatty changes and absence of necrosis after treatment with extract was observed, indicating satisfactory hepatoprotection.
The data obtained from animal experiments are expressed as mean ± SEM (standard error of mean). For statistical analysis data were subjected to analysis of variance (ANOVA) followed by Student’s t-test. Values are considered statistically significant at p < 0.01 for ANOVA and P < 0.05 for t-test.
Keywords: Withania somnifera, Hepatoprotective activity, Alkaline Phosphate, Aspartate amino trasferase, Alanine amino transferase.
Cite This Article:
Please cite this article in press Bollu Satya Sudha et al., Evaluation Of Hepatoprotective Activity Of Ethanolic Extract Of Withania Somnifera In Induced Liver Injury In Rats , Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Shanmugasundaram P, Venkataraman S (2006). Hepatoprotective and antioxidant effects of Hygrophila auriculata (K. Schum) Heine Acanthaceae root extract. Journal of Ethnopharmacology 104: 124-128.
2. Saleem TSM, Chetty CM, Ramkanth S, Rajan VST, Kumar KM, Gauthaman K (2010). Hepatoprotective herbs – a review. International Journal of Research in Pharmaceutical Sciences 1: 1-5.
3. Kaplowitz N, Tsukamoto H (1996). Oxidative stress and liver disease. Progress in Liver Diseases 14: 131-159.
4. Ajith TA, Hema U, Aswathy MS (2007). Zingiber officinale Roscoe prevents acetaminophen-induced acute hepatotoxicity by enhancing hepatic antioxidant status.
1. Food and Chemical Toxicology 45: 2267-2272.
5. Timbrell J (2001). Introduction to Toxicology. 3rd ed. Taylor and Francis, New York, pp. 57-71.
6. Kohen R, Nyska A (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicologic Pathology 30: 620-650.
7. Gupta AK, Misra N (2006). Hepatoprotective activity of aqueous ethanolic extract of Chamomile capitula in paracetamol intoxicated albino rats. American Journal of Pharmacology and Toxicology 1: 17-20.
8. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SPS (2008). Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. Medicinal Research Reviews 28: 746-772.
9. Kohle C, Schwarz M, Bock KW (2008). Promotion of hepatocarcinogenesis in humans and animal models. Archives of Toxicology 82: 623-631.
10. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ (1999). Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117: 669-677.
11. Seki S, Kitada T, Sakaguchi H (2005). Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatology Research 33: 132-134.
12. Kitase A, Hino K, Furutani T, Okuda M, Gondo T, Hidaka I, Hara Y, Yamaguchi Y, Okita K (2005). In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. Journal of Gastroenterology 40: 617-624.
13. Albano E, Mottaran E, Occhino G, Reale E, Vidali M (2005). Role of oxidative stress in the progression of non-alcoholic steatosis. Alimentary Pharmacolcology and Therapeutics 22: 71-73.
14. Lee WM (2003). Acute liver failure in the United States. Seminars in Liver Disease 23: 217-226.
15. Cullen JM, Miller RT (2006). The role of pathology in the identification of druginduced hepatic toxicity. Expert Opinion on Drug Metabolism and Toxicology 2: 241-247.
16. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH (2001). Complementary and alternative medicine in chronic liver disease. Hepatology 34: 595-603.
17. Saller R, Meier R, Brignoli R (2001). The use of silymarin in the treatment of liver diseases. Drugs 61: 2035–2063.
18. Flora K, Hahn M, Rosen H, Benner K (1998). Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 93: 139-143.
19. Pascual C, Gonz R, Armesto J, Muriel P (1993). Effect of silymarin and silybinin on oxygen radicals. Drug Development Research 29: 73-77.
20. Mourelle M, Muriel P, Favari L, Franco T (1989). Prevention of CCl4 induced liver cirrhosis by silymarin. Fundamental and Clinical Pharmacology 3: 183-191.
21. Pradhan SC, Girish C (2006). Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian Journal of Medical Research 124: 491-504.
22. Mukerjee AB, Dasgupta M (1970). Treatment of viral hepatitis by an indigenous drug Liv.52. Indian Practitioner 6: 357-366.
23. Charak Samhita, Vimanasthan (1981). Chapter I. Translated by P.V. Sharma, Chaukhamba Orientalia Publishers, Varanasi.
24. Radwan MA (2000). Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. Journal of Pharmacy and Pharmacology 52: 665-669.
25. Manoukian AV, Carson JL (1996). Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Safety 15: 64-71.
26. McGettigan MP, Henry D (2000). Current problems with non-specific COX inhibitors. Current Pharmaceutical Design 6: 1693-1724.
27. Rabinovitz M, Van Thiel DH (1992). Hepatotoxicity of nonsteroidal anti-inflammatory drugs. The American Journal of Gastroenterology 87: 1696-1704.
28. Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K, Schneemann M, Kullak-Ublick GA (2001). Fatal hepatotoxicity secondary to nimesulide. European Journal of Clinical Pharmacology 57: 321-326.